Zynerba Pharmaceuticals (NASDAQ:ZYNE) Research Coverage Started at Roth Capital

Roth Capital began coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a research report report published on Tuesday, April 30th, The Fly reports. The brokerage issued a buy rating and a $36.00 target price on the stock.

ZYNE has been the subject of a number of other reports. Zacks Investment Research raised Zynerba Pharmaceuticals from a hold rating to a buy rating and set a $7.00 price objective for the company in a research report on Friday, March 22nd. Cantor Fitzgerald reaffirmed a buy rating and set a $11.00 price objective on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. ValuEngine raised Zynerba Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, March 5th. HC Wainwright reaffirmed a buy rating on shares of Zynerba Pharmaceuticals in a research report on Monday,

... read more at: https://techknowbits.com/2019/05/16/zynerba-pharmaceuticals-zyne-coverage-initiated-by-analysts-at-roth-capital.html

Leave a Reply